InMed Pharmaceuticals Inc Cash Flow-to-Debt Ratio
InMed Pharmaceuticals Inc cash flow-to-debt ratio. InMed Pharmaceuticals Inc (INM) has a Cash Flow-to-Debt Ratio of -3.60x as of June 2026, meaning its operating cash flow of $-7.03 Billion could theoretically repay -4% of its total liabilities ($1.96 Billion) in one year. Check InMed Pharmaceuticals Inc (INM) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of InMed Pharmaceuticals Inc (2001–2026)
Cash flow-to-debt ratio of InMed Pharmaceuticals Inc from 2001 to 2026. Historical debt coverage capacity for InMed Pharmaceuticals Inc across 26 annual periods. Check INM capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
InMed Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2001–2026)
InMed Pharmaceuticals Inc cash flow-to-debt ratio by year from 2001 to 2026. Year-by-year debt coverage analysis for InMed Pharmaceuticals Inc. For the full cash flow conversion analysis, see INM cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -4.42x | $-8.64 Billion | $1.96 Billion | ▼ -66.4% |
| 2025 | -2.66x | $-7.77 Million | $2.92 Million | ▼ -36.1% |
| 2024 | -1.95x | $-6.99 Million | $3.58 Million | ▲ +28.4% |
| 2023 | -2.73x | $-7.28 Million | $2.67 Million | ▲ +16.5% |
| 2022 | -3.26x | $-15.58 Million | $4.78 Million | ▲ +0.9% |
| 2021 | -3.29x | $-9.79 Million | $2.97 Million | ▲ +14.1% |
| 2020 | -3.83x | $-7.37 Million | $1.92 Million | ▲ +48.0% |
| 2019 | -7.37x | $-8.77 Million | $1.19 Million | ▼ -42.8% |
| 2018 | -5.16x | $-3.68 Million | $713.02K | ▲ +38.0% |
| 2017 | -8.32x | $-2.37 Million | $284.24K | ▼ -883.3% |
| 2016 | -0.85x | $-386.07K | $456.17K | ▲ +96.7% |
| 2015 | -25.72x | $-1.61 Million | $62.51K | ▼ -181.1% |
| 2014 | -9.15x | $-641.38K | $70.11K | ▼ -1046.5% |
| 2013 | -0.80x | $-39.26K | $49.20K | ▲ +79.6% |
| 2012 | -3.92x | $-174.62K | $44.59K | ▲ +67.8% |
| 2011 | -12.16x | $-562.05K | $46.20K | ▼ -8272.6% |
| 2010 | -0.15x | $-195.42K | $1.35 Million | ▼ -252.5% |
| 2009 | 0.10x | $100.48K | $1.05 Million | ▲ +115.2% |
| 2008 | -0.63x | $-951.15K | $1.52 Million | ▲ +39.3% |
| 2007 | -1.03x | $-1.40 Million | $1.35 Million | ▼ -103.0% |
| 2006 | -0.51x | $-577.40K | $1.14 Million | ▼ -19.7% |
| 2005 | -0.42x | $-702.23K | $1.66 Million | ▲ +31.5% |
| 2004 | -0.62x | $-484.19K | $781.44K | ▲ +32.4% |
| 2003 | -0.92x | $-844.62K | $921.99K | ▲ +94.0% |
| 2002 | -15.36x | $-1.14 Million | $74.45K | ▼ -1505.2% |
| 2001 | -0.96x | $-471.69K | $493.02K | — |